Drug Profile
Research programme: anti-PD-1 monoclonal antibodies - PxRadia
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator PxRadia
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 10 Aug 2016 Preclinical trials in Cancer in USA (Parenteral)